Torrent Pharmaceuticals has completed the acquisition of Regestrone and Pregachieve brands in India from Swiss drug major Novartis AG.
The two brands are widely prescribed by gynaecologists for the management of abnormal uterine bleeding, post menopausal symptoms and infertility, Torrent said in a regulatory filing.
Women’s healthcare is an important therapy area for Torrent, which it intends to focus in the future, it added.
“Regestrone and Pregachieve will further fortify the hormone segment. The use of hormones amongst the gynaecologists is on an increase because of lifestyle changes,” the company said.
Last month, Torrent had announced inking of pacts with Novartis AG to acquire the two brands.
It, however, did not disclose financial details.
Torrent Pharma shares today ended 0.27% down at Rs 1,291 on BSE.